Skip to main content
. Author manuscript; available in PMC: 2023 May 15.
Published in final edited form as: Gastroenterology. 2021 Jul 2;161(4):1288–1302.e13. doi: 10.1053/j.gastro.2021.06.073

Figure 4. Cancer-Immunoprevention in Lynch Mice.

Figure 4.

Reduced tumor burden from combination NSAID and recurrent FSP neoantigen vaccination. (A) Recurrent FSP neoantigen vaccination in combination with NSAID prolongs overall survival of VCMsh2 mice. Kaplan-Meier survival curves of VCMsh2 mice treated with control (untreated), ASA, NAP, FSP vaccine, FSP vaccine with ASA or FSP vaccine with NAP as described in the methods.

(B) FSP vaccination and combination with NSAID treatment decreases tumor burden in VCMsh2 mice. Scatter dot plot representing tumor burden (sum of all intestinal tumor weights per mouse, [mg]) per mouse in cohorts of control (untreated), treated with ASA, NAP, FSP vaccine, FSP vaccine plus ASA or FSP vaccine plus NAP.Both panels present data updated from that originally presented in Figure S3 of PMID: 32641470, here including a larger cohort of control and naproxen treated VCMsh2 mice.